Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy

Information

  • Patent Grant
  • 8663210
  • Patent Number
    8,663,210
  • Date Filed
    Wednesday, May 12, 2010
    14 years ago
  • Date Issued
    Tuesday, March 4, 2014
    10 years ago
Abstract
A therapeutic energy system for performing interstitial laser therapy and brachytherapy includes two categories of components. The first category includes components usable to perform both interstitial laser therapy and brachytherapy. The second category of components includes components usable to perform either interstitial laser therapy or brachytherapy, but not both. The components co-act to apply therapeutic energy to tissue. The components of the first system include components inserted percutaneously into the tissue, such that interstitial laser therapy and brachytherapy can be performed sequentially without removing and re-inserting percutaneous components. Components of the second category include components not requiring additional puncturing of the skin of a patient, such that removing and inserting components of the second category from a patient is done easily and painlessly. An energy probe component does not maintain a cavity around the tumor mass. Surgical excision of tissue can be performed coincident to therapeutic energy treatment as disclosed.
Description
COPYRIGHT NOTICE

A portion of the disclosure of this patent document contains or may contain material which is subject to copyright protection. The copyright owner has no objection to the photocopy reproduction by anyone of the patent document or the patent disclosure in exactly the form it appears in the Patent and Trademark Office patent file or records, but otherwise reserves all copyright rights whatsoever.


DESCRIPTION

The present disclosure relates in general to a system and methods for applying therapeutic energy to a tissue mass, and in particular to an apparatus for applying x-ray energy and laser energy to a tumor mass and monitoring the dose of x-ray energy and temperature of the tissue adjacent to the tumor mass.


BACKGROUND

Percutaneous in situ or on-site laser therapy treatment of tissue such as tumors and in particular malignant breast tumors can be more readily performed today because tissue abnormalities such as tumors are being detected at earlier stages. Moreover, other treatment techniques can be performed in similarly early stages of the development of tissue abnormalities, such as the application of x-ray energy to a tissue abnormality. Tissue abnormalities such as breast cancer and other cancers or tumors detected early in development can be effectively treated or destroyed using an ablative agent such as laser energy without conventional surgery.


Interstitial laser treatments of tissue (such as tumors) including malignant tumors (such as breast, liver, brain, and neck tumors), have been in development for more than a decade. For example, U.S. Pat. No. 5,169,396, U.S. Pat. No. 5,222,953, U.S. Pat. No. 5,569,240, U.S. Pat. No. 5,853,366, U.S. Pat. No. 6,603,988, U.S. Pat. No. 6,701,175, U.S. Pat. No. 6,865,412, U.S. Pat. No. 7,041,109, and U.S. Pat. No. 7,171,253 disclose various apparatus and methods for applying laser energy directly to a tissue abnormality. Certain of these patents disclose a laser source for generating ablative laser energy to be applied to the tissue abnormality. Certain of these patents also disclose thermal probes including thermistors for detecting the temperature of tissue adjacent to tissue abnormalities.


In certain known treatment regimens, interstitial laser therapy is followed or preceded by chemotherapy, radiation therapy, or both. Currently available radiation therapy techniques require invasive steps beyond the minimally invasive techniques for performing interstitial laser therapy. For example, one radiation therapy technique includes creating an incision to enable radioactive seeds to be deposited at or near the tissue abnormality to be treated.


Furthermore, in certain other known treatment regimes, an apparatus for delivering energy to a tissue mass to be treated (such as a tumor mass) includes a catheter inserted in the vicinity of the tissue mass. In certain of such treatment regimes, the catheter is configured to maintain a cavity created as the tissue mass to be treated is destroyed (i.e., as the tissue mass is ablated). For example, in certain treatment regimes, the catheter includes a balloon which is inflated during treatment to maintain the cavity created by ablation of the tissue mass.


There is a need for a system to enable an integrated delivery modality that can deliver radiation to a treatment site in a controlled, minimally invasive way. There is a further need for devices for facilitating interstitial brachytherapy in a minimally invasive way. There is a further need for a therapeutic system including a plurality of components for applying therapeutic laser energy and therapeutic x-ray energy without removing or inserting one or more additional percutaneous components. There is a further need for a therapeutic system which enables delivery of radiation to a treatment site without the use of a catheter or balloon to maintain a cavity formed during treatment.


SUMMARY

Various embodiments of the therapeutic system disclosed herein enable an operator to conduct either interstitial laser therapy, brachytherapy, or both interstitial laser therapy and brachytherapy on the same tissue of interest. The disclosed system includes two general categories of components. The first category includes components usable to perform both interstitial laser therapy and brachytherapy. The second category includes components usable to perform either interstitial laser therapy or brachytherapy, but not both. For purposes of brevity of this application, the tissue of interest will sometimes be referred to as the “treated tissue” and will sometimes be referred to as the “tumor.” It should be appreciated that in different embodiments, the therapeutic energy system disclosed enables therapeutic energy to be applied to tissue other than tumors, or to tumors in locations of the body other than the breasts.


In one embodiment, the first category of components of the therapeutic system disclosed herein (i.e., the components usable to perform both interstitial laser therapy and brachytherapy) includes an energy probe configured to be positioned in the tumor, a sensing probe configured to detect a plurality of temperatures and a plurality of dosage amounts, at least one probe holder configured to position the energy probe and the sensing probe with respect to a stereotactic imaging device, and a computer configured to (a) control the amount of laser energy applied to the tumor; (b) control the amount of x-ray energy applied to the tumor; (c) monitor the temperature of the tissue adjacent to the tumor based on a plurality of received signals indicating a plurality of detected temperatures; and (d) monitor the dosage applied to the tumor mass based on a plurality of received signals indicating a plurality of detected dosage amounts. In this embodiment, the second category of components (i.e., the components usable to perform either interstitial laser therapy or brachytherapy but not both) includes a laser energy source, an x-ray energy source, an optical fiber configured to be connected to the laser energy source and to be removably inserted in the energy probe, an optical fiber configured to be connected to the x-ray energy source and to be removably inserted in the energy probe, and at least one controller configured to (a) receive a plurality of electrical signals from a plurality of sensors; (b) convert the received electric signals into a plurality of temperatures and a plurality of dosage amounts; and (c) send a plurality of signals indicating the converted temperatures and dosage amounts to the computer of the first category of components.


In one embodiment, the first category of components and the second category of components of the therapeutic system disclosed herein enable an operator to perform interstitial laser therapy before performing brachytherapy. Specifically, the therapeutic system disclosed enables an operator to configure the components of the first category of components with the interstitial laser therapy-specific components of the second category of components to apply controlled amounts therapeutic laser energy directly to a tumor and to monitor the temperature of the tissue adjacent to the tumor. In this embodiment, the therapeutic system then enables the operator to replace the interstitial laser therapy-specific components of the second category of components with the brachytherapy-specific components and to apply controlled amounts of therapeutic x-ray energy and monitor the dose(s) applied to the tumor.


In an alternative embodiment, the therapeutic system disclosed herein enables an operator to perform brachytherapy prior to performing interstitial laser therapy by utilizing the components of the first category of components with the brachytherapy-specific components of the second category of components to apply x-ray energy until a specific dosage is achieved. In this embodiment, the disclosed system enables the operator to remove the brachytherapy-specific components and utilize the interstitial laser therapy-specific components to apply laser energy until a specified tissue temperature is achieved for tissue adjacent to the tumor mass.


In one embodiment, the components of the system disclosed herein do not include any device or mechanism for maintaining a cavity formed during application of energy to treated tissue. In one such embodiment, the energy probe is configured such that the diameter of the energy probe is substantially constant throughout the length of the energy probe. In one embodiment, the diameter of the probe is relatively small compared to the diameter of the treated tissue. In this embodiment, the structure of the probe itself does not provide an artificial boundary to a cavity formed around the treated tissue. Thus, it should be appreciated that the energy probe in one embodiment is configured not to maintain a cavity formed during application of therapeutic energy—that is, the energy probe does not include a device, such as an inflatable balloon, for maintaining a cavity during treatment.


In one embodiment, the system disclosed herein enables a surgical excision of tissue, such as a lumpectomy, to be performed coincident to application of therapeutic energy to the tissue. In this embodiment, the disclosed system enables an operator to enhance or improve upon results obtainable using such known surgical excision techniques, increasing an overall effectiveness of the treatment of the tissue.


It should be appreciated that combining the components of the first category of components with the brachytherapy-specific components of the second category of components enables the operator to accurately deliver x-ray energy to a tumor. It should be further appreciated that combining the components of the first category of components with the interstitial laser therapy-specific components of the second category of components enables the operator to accurately deliver laser energy to the tumor.


It is therefore an advantage of the present disclosure to provide a therapeutic system for performing interstitial laser therapy and also for performing interstitial brachytherapy wherein the temperature of the tissue adjacent to the tumor mass and the dosage applied to the tumor are respectively monitored.


It is a further advantage of the present disclosure to provide a system for performing interstitial laser therapy and brachytherapy wherein the system includes a plurality of components which are usable to perform both interstitial laser therapy and brachytherapy.


It is a further advantage of the present disclosure to provide a system for performing interstitial laser therapy and brachytherapy which does not require an additional structure, such as a balloon, for maintaining a cavity during treatment.


It is a further advantage of the present disclosure to provide a system for performing interstitial laser therapy and brachytherapy which is usable coincident to known techniques for surgical excision of tissue to enhance the results of a treatment.


It is a further advantage of the present disclosure to provide a therapeutic energy system to enable an operator to apply laser energy and x-ray energy to tissue of interest which saves operator time, saves money on the cost of the components of the disclosed system, decreases patient discomfort, decreases the number of components to be sterilized, increases the accuracy of the point where therapeutic energy is delivered, reduces the number of needle sticks, increases the precision with which amounts of therapeutic energy are applied to tissue of interest such as a tumor mass, and increases the options available to treat tissue of interest such as a tumor mass.


Additional features and advantages of the present invention are described in, and will be apparent from, the following Detailed Description of Exemplary Embodiments and the figures.





DESCRIPTION OF THE DRAWINGS


FIG. 1 is a schematic diagram of the components in two categories of components required to perform both interstitial laser therapy and brachytherapy.



FIGS. 2A and 2B are portions of a flow chart illustrating an example process for performing interstitial laser therapy and brachytherapy using the components of the two disclosed categories.



FIG. 3 is a fragmentary perspective view of an imaging unit, a stereotactic device, and an umbilical assembly of an apparatus for performing interstitial laser therapy and brachytherapy.



FIG. 4 is a fragmentary perspective view of one embodiment of the energy probe disclosed herein.



FIG. 5 is a fragmentary perspective view of one embodiment of the sensing probe disclosed herein.



FIG. 6 is a fragmentary perspective view of the apparatus for performing interstitial laser therapy and brachytherapy, including the components in the two disclosed categories configured to perform interstitial laser therapy.



FIG. 7A is a schematic diagram of a conventional balloon catheter-based brachytherapy apparatus.



FIG. 7B is a schematic diagram of a brachytherapy apparatus, which does not operate in a cavity and thus does not require a balloon or other device to maintain the cavity, as disclosed herein.





DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS

Referring now to FIG. 1, a schematic diagram of the components of each category of the disclosed system is illustrated. It should be appreciated that the schematic diagram of FIG. 1 is not drawn to scale, nor are the components drawn to accurately represent the shape or size of the component. For example, it should be appreciated that the sensing probe 102 in a preferred embodiment includes a trocar on the percutaneously inserted end, though as illustrated in FIG. 1 the sensing probe does not include such a tip. Moreover, it should be appreciated that solid lines connecting components of the disclosed system indicate an electrical connection. Dashed lines, on the other hand, represent an optical path configured to enable optical energy to be transmitted.



FIG. 1 indicates that the disclosed therapeutic system includes two categories of components, referred to as category one and category two. It should be appreciated that in various embodiments of the therapeutic system disclosed herein, the components of the first category (i.e., components usable to perform both interstitial laser therapy and brachytherapy) include each of the components inserted percutaneously and each of the components used to position the percutaneously positioned components. These embodiments enable an operator to switch between performing interstitial laser therapy and performing brachytherapy without removing or re-inserting any percutaneously positioned components, thus reducing patient discomfort and maintaining repeatable, accurate probe positioning.


Referring first to items of category one, the disclosed system includes a plurality of components usable to perform both interstitial laser therapy and brachytherapy. As illustrated, the components of category one includes an energy probe 100, a sensing probe 102, and at least one probe holder 50. Category one system also includes a computer system 110 configured to receive a plurality of signals indicating quantities of applied energy, and configured to send a plurality of signals indicating changes in the amount of energy applied based on the received signals indicating quantities of applied energy. In the illustrated embodiment, the probe holder 50 is configured to position the energy probe 100 and the sensing probe 102 with respect to a tumor mass 10 of a body part 1 such as a breast. As illustrated, the probe holder 50 is configured to position the energy probe 100 such that the tip of the energy probe 100 is in the center of the tumor mass 10. The probe holder 50 is configured to position the sensing probe 102 such that the plurality of sensors 102d of the sensing probe are adjacent to the tumor mass 10 to sense indicators of applied therapeutic energy of tissue adjacent to the tumor mass 10.


The components included in category two of the disclosed therapeutic system include components usable to perform either interstitial laser therapy or brachytherapy, but not both. In the illustrated embodiment, category two includes a plurality of energy sources such as a laser energy source 140 and an x-ray energy source 150. It should be appreciated that the laser energy source 140 is configured to emit laser energy into an appropriate optical fiber configured to deliver laser energy. It should be further appreciated that the x-ray energy source 150 is configured to emit x-ray energy into an appropriate optical fiber configured to deliver x-ray energy.


Category two also includes a plurality of optical fibers such as a laser optical fiber 104 and an x-ray optical fiber 105. In the illustrated embodiment, the laser optical fiber 104 is configured to be removably attachable to the laser energy source 140. The laser optical fiber 104 is further configured to transmit laser energy along the length of the laser optical fiber and to deliver the energy as light energy at the tip of the laser optical fiber. Similarly, the x-ray optical fiber 105 is configured to be removably attachable to the x-ray energy source 150. The x-ray optical fiber 105 is configured to transmit any x-ray energy emitted by the x-ray energy source 150 along the length of the fiber and to emit the energy as x-ray energy at the tip of the x-ray optical fiber 105.


The components of category two further include a plurality of controllers configured to convert electrical signals to values indicating an amount of energy applied to the tumor mass 10. In the illustrated embodiment, the therapeutic system includes two controllers including a thermistor controller 240 and a dosimeter controller 250. In this embodiment, the thermistor controller 240 is configured to convert a plurality of electrical signals indicating a plurality of detected resistances into a plurality of temperatures. The dosimeter controller 250 is similarly configured to convert a plurality of electrical signals indicating a plurality of changes in charge difference between a plurality of pairs of electrodes of a plurality of dosimeters into a plurality of dosage amounts.


Referring still to FIG. 1, the components of category one are configured to be combined with the components of category two to enable an operator to perform both interstitial laser therapy and brachytherapy. It should be appreciated that the embodiment of the disclosed therapeutic system illustrated in FIG. 1 does not distinguish between whether the therapeutic system is configured to perform interstitial laser therapy or brachytherapy—rather, the illustrated embodiment indicates the interactions between the various components of both categories to perform either interstitial laser therapy or brachytherapy.


In the illustrated embodiment, the energy probe 100 is configured to be positioned in the tumor mass 10 of the body part to be treated 1 using the at least one probe holder 50. The sensing probe 102 is configured to be positioned relative to the energy probe 100 using the at least one probe holder 50.


The energy probe 100 is configured to be connected to the thermistor controller 240 and the dosimeter controller 250 using the energy probe wire 100c. In this embodiment, the energy probe 100 includes at least one thermistor 100e and at least one dosimeter 100e positioned on the tip of the probe 100 and configured to detect a tissue temperature or a dosage amount of the tumor mass 10. It should be appreciated that in various embodiments, the energy probe 100 does not include any sensor 100e such as a thermistor or a dosimeter. In these embodiments, the energy probe does not include an energy probe wire 100c and is not configured to be connected to the thermistor controller or the dosimeter controller.


In the illustrated embodiment, the energy probe 100 is configured to have a substantially constant diameter throughout the length of the probe 100. In the illustrated embodiment, the diameter of the energy probe 100 is relatively small compared to a diameter of the tumor mass 10. Thus, it should be appreciated that in the illustrated embodiment, the energy probe 100 is not configured to maintain a cavity approximating the shape and size of the tumor mass 10 during application of therapeutic energy to the tumor mass 10. That is, the energy probe 100 is not dimensioned (and does not include an additional structure, such as a balloon) to maintain a cavity within the body part 1 approximating the dimensions of the tumor mass 10 to which therapeutic energy is applied.


In one embodiment, a stylet 100b (not shown) is configured to be removable from the cannula 100a after the stylet has been inserted in the tumor mass 10. In this embodiment, removing the stylet 100b enables an optical fiber to be inserted in the energy probe 100. In one embodiment, the laser optical fiber 104 is configured to be inserted in the energy probe 100 after having been attached to the laser energy source 140. In this embodiment, the laser energy probe is configured to deliver laser energy emitted by the laser energy source 140 to the tumor mass 10 in which the energy probe 100 is positioned. In another embodiment, the x-ray optical fiber 105 is configured to be inserted in the energy probe 100 after having been attached to the x-ray energy source 150. In this embodiment, the x-ray optical fiber 105, already connected to the laser energy source, is configured to deliver x-ray energy emitted by the x-ray energy source 150 to the tumor mass 10 in which the energy probe is positioned. It should be appreciated that in one embodiment, the energy probe 100 is configured such that only one of the laser optical fiber 104 and the x-ray optical fiber 105 is insertable in the energy probe 100 at once.


The sensing probe 102 is configured to be connected to the plurality of controllers such as the thermistor controller 240 and the dosimeter controller 250. In the illustrated embodiment, the sensing probe 102 is configured to so connect to the plurality of controllers using the sensing probe wire 102a. As discussed above, the sensing probe wire 102a is configured to carry electrical signals from the plurality of sensors 102d of the sensing probe to the controllers 240 or 250. In one embodiment, the sensing probe wire 102a is also configured to carry a plurality of signals from the dosimeter controller 250 to the dosimeters 102d including energy to maintain charge differences between a plurality of pairs of electrodes the dosimeters.


The computer system 110 is a component of category one, meaning that it is configured to be usable to perform both interstitial laser therapy and brachytherapy. In one embodiment, the computer system 110 includes at least one microprocessor, at least one memory device, at least one display device, at least one input device, at least one interface device for receiving a plurality of signals from a plurality of sensing controllers, and at least one interface device for sending a plurality of signals to a plurality of energy sources. In the illustrated embodiment, the computer system 110 is connected to the thermistor controller 240 and the dosimeter controller 250, and is further connected to the laser energy source 140 and the x-ray energy source 150. In this embodiment, the computer is configured to receive a plurality of signals from the thermistor controller 240 indicating temperatures sensed by the plurality of thermistors of the sensing probe 102. The computer 110 is also configured to receive a plurality of signals from the dosimeter controller 250 indicating dosages detected by the plurality of dosimeters of the sensing probe.


The computer 110 is further configured in one embodiment to store data indicative of the received signals to track the progress of interstitial laser therapy and brachytherapy performed with the disclosed therapeutic system. In one embodiment, the computer system 110 is configured to store each received temperature in a database associated with a patient having the body part 1, and is further configured to store each received dosage amount in the same database. In a further embodiment, the computer 110 is configured to display on the at least one display device a graphical representation of the received signals indicating a plurality of temperatures and a plurality of dosage amounts. In various embodiments, the computer is configured to display a bar graph wherein each bar indicates a temperature of a single thermistor or a dosage of a single dosimeter.


In one embodiment, the computer 110 is further configured to send a plurality of signals to the plurality of energy sources including the laser energy source 140 and the x-ray energy source 150 to change the amount of energy emitted. In one embodiment, if the temperature detected by one or more of the plurality of thermistors of the sensing probe 102 exceeds a predetermined maximum temperature, the computer 110 is configured to send a signal to the laser energy source 140 to cause the laser energy source to stop emitting laser energy. In another embodiment, if a dosage amount detected by one of the dosimeters of the sensing probe 102 exceeds a predetermined maximum dosage amount, the computer 110 is configured to send a signal to the x-ray energy source 150 to cause the x-ray energy source to stop emitting x-ray energy. In various embodiments, once the predetermined maximum temperature or the predetermined maximum dosage amount has been detected, the computer is configured to continue receiving signals indicating temperatures or dosages. In one embodiment, the computer is configured to send a signal to cause the laser energy source 140 to resume generating laser energy when at least one of the thermistors of the sensing probe 102 indicates a temperature below a predefined resume treatment temperature.


It should be appreciated that in various embodiments, one or more components illustrated as belonging to category one in FIG. 1 are configured to be usable to perform interstitial laser therapy or brachytherapy, but not both. For example, in one embodiment, the therapeutic system disclosed herein includes at least two sensing probes. In this embodiment, one of the sensing probes includes a plurality of thermistors for measuring a plurality of temperatures during interstitial laser therapy, and one of the sensing probes includes a plurality of dosimeters for measuring a plurality of dosage amounts during brachytherapy. In this embodiment, between performing interstitial laser therapy and brachytherapy, an operator removes one of the plurality of sensing probes from the at least one probe holder 50 and inserts the other sensing probe in the at least one probe holder 50. It should be appreciated that removing and replacing the sensing probes enables an operator to position the sensing probes at different distances from the energy probe.


In various embodiments, one or more components of category two are configured to be usable to perform both interstitial laser therapy and brachytherapy. For example, in one embodiment the laser optical fiber 104 and the x-ray optical fiber 105 are a single energy optical fiber. In this embodiment, the energy optical fiber and is configured to transmit laser energy and x-ray energy to the tumor mass 10. It should be appreciated that with a single energy optical fiber, an operator in one embodiment removes the energy optical fiber form the laser energy source and connects it to the x-ray energy source, or vice versa, to switch from between performing interstitial laser therapy and brachytherapy.


In various embodiments, the laser energy source 140 and the x-ray energy source 150 are enclosed in a single energy source enclosure. In this embodiment, the laser optical fiber 104 and the x-ray optical fiber 105 are configured to be attachable to different connectors on the same energy source enclosure. In a further embodiment, the combined energy source enclosure includes a single energy connector for connecting the x-ray optical fiber and the laser optical fiber. In this embodiment, an electro-mechanical mechanism within the combined energy source enclosure is configured to switch from emitting laser energy to x-ray energy. In one embodiment, this switch is actuated by a signal sent from the computer 110.



FIGS. 2A and 2B illustrate different components 600a and 600b of a flow chart of an example process for using the therapeutic system disclosed herein to perform both interstitial laser therapy and brachytherapy. Although the example process 600a and 600b for performing interstitial laser therapy and brachytherapy is described with reference to the flow chart illustrated in FIGS. 2A and 2B, it should be appreciated that the system disclosed herein discloses other processes for performing interstitial laser therapy and brachytherapy using the therapeutic system disclosed herein. For example, the order of many of the blocks may be changed, and many of the blocks described are optional.


To begin performing either interstitial laser therapy or brachytherapy using the disclosed therapeutic system, an operator positions the components of category one. Referring to process 600a of FIG. 2A, to do this, the operator positions at least one probe holder using the probe holder attachments of the stereotactic imaging device, as indicated by block 602. Next, the operator positions the energy probe in the probe holders and into the tumor mass, as indicated by block 604. After determining the appropriate position of the sensing probe with respect to the energy probe, the operator inserts the sensing probe through the probe holder and into the tissue adjacent to the tumor mass, as indicated by block 606. The operator in one embodiment completes the set-up of the components of category one by connecting the energy probe wire and the sensing probe wire to the connector box, as indicated by block 608. It should be appreciated that by so configuring the components of the disclosed therapeutic system, the computer is configured to receive the appropriate signals indicating a plurality of dosages and a plurality of temperatures such that an appropriate display can be generated and such that the amount of therapeutic energy applied can be modified accordingly.


As discussed above, the therapeutic system disclosed herein enables an operator to perform both interstitial laser therapy and brachytherapy. Therefore, after the components of category one are configured as discussed with respect to blocks 602, 604, 606, and 608, the operator must determine whether to perform interstitial laser therapy or brachytherapy, as indicated by block 610. It should be appreciated that this determination dictates which of the components of category two are used first. If the operator wishes to perform interstitial laser therapy, the operator connects the laser optical fiber of category two to the laser energy source of category two and inserts the fiber in the energy probe, as indicated by block 612. The operator additionally configures the thermistor controller to send a plurality of signals indicating a plurality of detected temperatures to the computer, as indicated by block 614. Finally, the operator activates the laser energy source, which emits laser energy that is transmitted through the laser optical fiber and applied to the tumor mass, until a predefined temperature or set of temperatures is reached in the tissue adjacent to the tumor mass, as indicated by block 616. In an alternative embodiment, the laser energy source is configured to emit laser energy until a predefined amount of energy has been applied to the tumor mass.


Referring now to FIG. 2B, upon completion of interstitial laser therapy, the operator determines whether to perform brachytherapy, as indicated by block 618. If the operator decides not to perform brachytherapy, the operator removes the optical fiber from the energy probe and removes the energy probe and the sensing probe from the tumor and the tissue adjacent to the tumor, thus finishing therapeutic treatment, as indicated by block 628. If the operator determines that the therapeutic system disclosed should be used to perform brachytherapy, the operator removes the laser optical fiber from the energy probe and disconnects the fiber from the laser energy source, as indicated by block 620. The operator then connects the x-ray optical fiber to the x-ray energy source and inserts the fiber in the energy probe, such that the tip of the optical fiber is even with the tip of the energy probe, as indicated by block 622. The operator configures the dosimeter controller to send a plurality of detected dosage amounts detected by the plurality of dosimeters of the sensing probe to the computer, as indicated by block 624. Finally, the operator applies x-ray energy until a predefined dosage amount is detected by the dosimeters of the sensing probe, as indicated by block 626. Once the predefined dosage amounts have been detected and the x-ray energy source has stopped emitting x-ray energy through the x-ray optical fiber, the operator removes the optical fiber from the energy probe, removes the probes from the tumor mass and the tissue adjacent to the tumor mass, and finishes therapeutic treatment, as indicated by block 628.


Referring again to FIG. 2A, if, after initially configuring the components of category one, the operator determines that brachytherapy should be performed first, as indicated by block 610, the operator connects the x-ray optical fiber to the x-ray energy source and inserts the fiber in the energy probe, as indicated by block 630. The operator configures the dosimeter controller to send a plurality of signals indicating a plurality of detected dosage amounts to the computer for monitoring the progress of the brachytherapy treatment, as indicated by block 632. The operator then performs brachytherapy by activating the x-ray energy source to apply x-ray energy until a predefined dosage amount is detected in the tissue adjacent to the tumor mass, as indicated by block 634.


Referring again to FIG. 2B, upon completion of the brachytherapy treatment described, the operator determines whether to perform interstitial laser therapy, as indicated by block 636. If the operator determines that such interstitial laser therapy is not necessary, the operator removes the optical fiber from the energy probe and removes the energy probe and the sensing probe from the tumor mass and from the tissue adjacent to the tumor mass, as indicated by block 628. If, however, the operator determines that interstitial laser therapy following brachytherapy is appropriate, the operator removes the x-ray optical fiber from the energy probe and disconnects the x-ray optical fiber from the x-ray energy source, as indicated by block 638. The operator then connects the laser optical fiber to the laser energy source and inserts the laser optical fiber in the energy probe, indicated by block 640. The operator configures the thermistor controller to send a plurality of signals indicating a plurality of detected temperatures to the computer to enable the operator to monitor the progress of the interstitial laser therapy, as indicated by block 642. Finally, the operator causes the laser energy source to emit laser energy, such that laser energy is applied to the tumor mass until a predefined temperature is detected by the thermistors in the tissue adjacent to the tumor mass, as indicated by block 644. When the determined temperatures have been reached, the operator removes the optical fiber from the energy probe and removes the probes from the tumor mass and from the tissue adjacent to the tumor mass, as indicated by block 628.


It should be appreciated that in various embodiments, the process illustrated by portions 600a and 600b includes performing each of interstitial laser therapy and brachytherapy more than once, until the operator determines that the appropriate amount and type of therapeutic energy has been applied to the tumor mass.



FIG. 3 illustrates an embodiment of an imaging unit usable with a stereotactic device and further usable with the components disclosed herein to perform both interstitial laser therapy and brachytherapy. Specifically, FIG. 3 illustrates an imaging device or unit such as a conventional rotatable or positionable digital mammography device or unit 12. The mammography unit 12 includes a suitable stereotactic device or unit 14. It should be appreciated that the imaging device or unit may be any suitable unit or device including but not limited to x-ray, ultrasound, or magnetic resource imaging devices. It should also be appreciated that the stereotactic device or unit may be any suitable device or unit. The illustrated stereotactic device 14 includes aligned extendable upper (or first) and lower (or second) probe holder attachments 16a and 16b, respectively, suitably attached at the bottom of the stereotactic device 14. The illustrated stereotactic device 14 includes a compression plate 18 suitably attached at the bottom of the stereotactic device 14 below the upper and lower biopsy needle holders 16a and 16b. For ease of illustration, FIG. 3 shows a saline bag instead of a body part (such as a breast) containing the tissue which would be treated using the interstitial laser energy treatment apparatus.



FIG. 3 further illustrates an umbilical assembly including an umbilical cable 22 and a connector box 24. In the illustrated embodiment, the umbilical assembly includes a plurality of conductors to connect various ones of the components disclosed herein to a plurality of the disclosed components located remotely from the mammography unit 12. In the illustrated embodiment, the connector box 24 and the umbilical cable 22 include a plurality of conductors for transmitting electrical signals and at least one optical fiber for transmitting optical energy.


In the illustrated embodiment, the connector box 24 includes a plurality of sockets 26 and 28 and at least one fiber optic cable connector 30. The sockets 26 and 28 are labeled Energy Probe and Sensing Probe, respectively. In an alternative embodiment, the connector box includes two or more fiber optic cable connectors such as connector 30, and the umbilical cable includes at least two optical fibers for connecting the connectors such as connector 30 to a plurality of energy sources configured to emit optical energy located remotely from the mammography unit 12.


Referring now to FIG. 4, an example embodiment of the energy probe 100 is illustrated. In the illustrated embodiment, the energy probe 100 includes a hollow cannula 100a. The energy probe also includes a stylet 100b configured to be removably insertable in the cannula 100a. In one embodiment, when the stylet is inserted in the cannula, the energy probe enables an opening to be formed in the skin by puncturing the skin such that the tip of probe is positionable percutaneously in the tumor mass.


The energy probe 100 also includes at least one sensor 100e. In the illustrated embodiment, the sensor 100e is connected to an energy probe connector 100d by way of a sensor wire 100c. In one embodiment, the sensor is a thermistor and is configured to detect a resistance and to send an electrical signal to the energy probe connector 100d indicative of a detected temperature at the tip of the energy probe 100. In another embodiment, the sensor 100e is a dosimeter configured to measure a dosage amount at the tip of the energy probe 100. In various embodiments, the energy probe includes a plurality of sensors such as sensor 100e for measuring temperature and dosage at the tip of the energy probe. It should be appreciated that in these embodiments, the electronic signals indicating a detected temperature and/or dosage for each of the sensors such as sensor 100e travel through the sensor wire 100c and into the connector 100d.


The energy probe is configured to be insertable through at least one probe holder, as discussed in detail below. The energy probe is also configured such that when the stylet 100b is removed from the cannula 100a, at least one optical fiber is insertable in the energy probe 100. In various embodiments, the cannula 100a of the probe 100 is further configured to enable an optical fiber and a volume of liquid to be positioned in the probe. In various embodiments, the liquid is saline and functions as a heat-transfer medium, as discussed below.


As discussed above, in the embodiment of the energy probe 100 illustrated in FIG. 4, the diameter of the energy probe 100 is substantially constant throughout the length of the energy probe 100. Moreover, as discussed above with respect to FIG. 1, the diameter of the energy probe 100 in various embodiments is relatively small compared with the diameter of a tumor mass to be treated. Thus, it should be appreciated that the energy probe 100 illustrated in FIGS. 1 and 4 is not configured to maintain a cavity approximating the size of the tumor mass during application of therapeutic energy as described herein.



FIG. 5 illustrates an example embodiment of the sensing probe 102 disclosed herein. The sensing probe 102 includes a sensor wire 102a which his configured to send electrical signals representing a plurality of conditions sensed by the sensing probe to a connector 102b. The sensing probe 102 also includes a plurality of evenly spaced-apart marks 102c for positioning the sensing probe with respect to the energy probe, as discussed below.


The sensing probe further includes a plurality of sensors 102d. In one embodiment, the sensors 102d are thermistors configured to sense a plurality of resistances. In this embodiment, each thermistor 102d is connected by a conductor (not shown) to the sensing probe wire 102a, which in turn communicates the signals indicative of detected resistances to the connector 102b.


In another embodiment, the sensors 102d are a plurality of dosimeters configured to measure a plurality of charge differences between two electrodes. In this embodiment, each of the sensors 102d is connected by an appropriate conductor to the sensor wire 102a. The conductors are configured to send electronic signals indicative of a plurality of charge differences to the connector 102b. In various embodiments, the conductors are also configured to deliver electrical charge to two electrodes of each dosimeter 102d to maintain any required charge difference between the electrodes.


In various embodiments, the sensors 102d include a plurality of thermistors for measuring a plurality of temperatures and a plurality of dosimeters for measuring a plurality of dosage amounts. In this embodiment, it should be appreciated that a single sensing probe enables an operator to determine the amount of energy applied to a tumor based on the temperature of tissue adjacent to the tumor and based on the dosage amount received by tissue adjacent to the tumor. Thus, a sensing probe 102 including at least one dosimeter and at least one thermistor enables an operator to perform both interstitial laser therapy and brachytherapy.


The sensing probe is configured to be insertable in at least one probe holder, as discussed below. In this embodiment, the sensing probe is further configured to be positioned with respect to the energy probe based on the plurality of evenly spaced-apart marks 102c of the sensing probe. The sensing probe is also configured to include a trocar or other appropriate structure on the tip of the probe such that pressure applied to the sensing probe enables the sensing probe to puncture the skin such that the plurality of sensors 102e are positionable adjacent to a percutaneous tumor.


In an alternative embodiment, the therapeutic system disclosed herein includes at least two sensing probes such as sensing probe 102 wherein at least one sensing probe is a thermal probe and wherein at least one sensing probe is a dosage probe. In this embodiment, the at least one thermal probe includes one or more thermistors for measuring one or more temperatures of tissue adjacent to the tissue of interest, and the at least one dosage probe includes one or more dosimeters for measuring one or more dosage amounts of tissue adjacent to the tissue of interest.



FIG. 6 illustrates an example embodiment of the components of category one combined with the components of category two. It should be appreciated that FIG. 6 does not illustrate the plurality of energy sources, the plurality of sensor controllers, or the computer. In the illustrated embodiment, the umbilical cable 22 and the connector box enable the illustrated components illustrated to co-act with the plurality of energy sources, the plurality of sensor controllers, and the computer.


In the illustrated embodiment, the energy probe 100 is positioned in the tumor mass 10 (which, as noted above, is illustrated as a saline bag). The probe holders 50 are configured to be rotatably insertable in the probe holder attachments 16a and 16b. In the illustrated embodiment, two probe holders 50 thus position the energy probe with respect to the tumor mass 10. In the illustrated embodiment, the energy probe 100 includes at least one thermistor and at least one dosimeter positioned near the tip of the energy probe. The energy probe wire 100c is configured to be connectable to the umbilical box such that a plurality of conductors within the energy probe wire 100c enable electrical signals to be sent from the at least one dosimeter and the at least one thermistor to the connector box 24. As illustrated, the energy probe wire 100c is connected to the connector box 24 by way of the energy probe socket 26. It should be appreciated that at least one wire of the umbilical cable 22 is configured to further send these electrical signals to the appropriate energy controller 240 or 250.


The probe holders 50 are further configured to position the sensing probe 102 with respect to the tumor mass 10. In the illustrated embodiment, the sensing probe 102 includes a plurality of thermistors and a plurality of dosimeters 102d (not shown) mounted near the end of the sensing probe inserted in the tissue adjacent to the tumor mass. Moreover, the sensing probe 102 includes a sensing probe wire 102a which includes a plurality of conductors for sending electrical signals indicating a plurality of temperatures or a plurality of dosage amounts to the connector box 24. In the illustrated embodiment, a single wire 102a includes each of the conductors for sending a signal from each dosimeter and each thermistor. As illustrated, the sensing probe wire 102a is configured to be connected to the connector box 24 by way of sensing probe socket 28. It should be appreciated that at least one wire of the umbilical cable 22 is configured send these electrical signals to the appropriate energy controller 240 or 250.


The configuration of the components of the disclosed therapeutic system illustrated in FIG. 6 enables an operator to perform interstitial laser therapy. In this embodiment, a hemostasis valve 60 is removably connected to the energy probe 100. The hemostasis value 60 includes three ports. One of the ports is connected to the energy probe, and one of the ports enables a flow of a liquid to act as a heat transfer medium, such as saline, and one of the ports enables a laser optical fiber 104 to be inserted through the hemostasis valve 60 and into the energy probe 100. In the illustrated embodiment, saline is provided to the energy probe 100 by way of saline tube 114. In the illustrated embodiment, the laser optical fiber 104 is positioned in the hemostasis valve and further in the energy probe 100 such that the tip of the laser optical fiber 104 is even with the tip of the energy probe 100. Moreover, the laser optical fiber 104 is connected to the connector box 24 by way of the optical fiber connector 30.


It should be further appreciated that the disclosed therapeutic system, illustrated in FIG. 6, enables an operator to easily and quickly switch from performing interstitial laser therapy to performing brachytherapy. In the illustrated embodiment, to switch from performing interstitial laser therapy to performing brachytherapy, the operator removes the laser optical fiber 104 and the hemostasis valve 60 from the energy probe 100. The operator also disconnects the laser optical fiber 104 from the connector box 24. To perform brachytherapy, the operator connects the x-ray optical fiber 105 to the connector box 24 and inserts the x-ray optical fiber 105 in the energy probe 100. The operator finally makes any necessary changes with respect to the x-ray energy source 150 (such as changing a connector from the umbilical cable 22 from the laser energy source 140 to the x-ray energy source 150). After the operator has performed the above actions, the disclosed therapeutic system is configured to perform brachytherapy by applying x-ray energy to the tumor.



FIG. 7A is a schematic diagram 700a of a conventional balloon catheter-based brachytherapy apparatus. FIG. 7A illustrates a schematic view of a body part to be treated in the form of breast 702. In the illustrated embodiment, a cavity 706 has been previously formed by an operator performing a surgical procedure, such as a lumpectomy, as is known in the art. A catheter 704 is inserted into the body part to be treated 702 and into the cavity 706. In the illustrated embodiment, in order to ensure accurate delivery of therapeutic energy (i.e., x-ray energy), the apparatus of FIG. 7A, includes a balloon 708 or other appropriate structure to ensure that the cavity 706 remains uniform and does not collapse during treatment. In a further embodiment, conventional brachytherapy apparatus such as those illustrated in FIG. 7A require that the balloon 708 be inflated until the cavity 706 attains a spherical or substantially spherical shape. Thus, it should be appreciated that conventional apparatus such as the apparatus illustrated in FIG. 7A require a balloon 708 or other device to ensure the integrity and uniformity of the cavity 706 during therapy.



FIG. 7B is a schematic diagram 700b of an embodiment of the disclosed brachytherapy apparatus, which does not operate in a cavity and thus does not require a balloon or other device to maintain the cavity. In the embodiment illustrated in FIG. 7B, the body part to be treated remains the breast 702. In the illustrated embodiment, however, no cavity has been created during a treatment preceding brachytherapy, such as during the interstitial laser therapy treatment described herein. Thus, the zone of treatment 714 for brachytherapy does not include a cavity, but rather includes substantially uniform tissue mass, illustrated as a cross-hatched area of tissue mass, which will not collapse or otherwise deform during treatment. Since tissue mass 714 does not include a cavity, the apparatus disclosed herein does not require a balloon or other device to maintain a cavity during brachytherapy. Thus, the illustrated embodiment of the disclosed apparatus includes a probe 710 with a fiber 712 inserted therethrough, wherein the tip of the probe/fiber combination is approximately centered in the tissue mass 714. During brachytherapy performed using the illustrated embodiment of the disclosed apparatus, an operator applies x-ray energy to the fiber 712, which energy is directed into the tissue mass 714, and therapeutically applied to the breast 702. Moreover, due to the physical properties of tissue to be treated, the energy delivered during brachytherapy will be delivered in a substantially spherical pattern—a result which could only be achieved in the prior art by using a balloon or other similar device to force a cavity into a spherical shape.


It should thus be appreciated that because the disclosed brachytherapy treatment and apparatus is utilized in conjunction with interstitial laser therapy as described herein, no balloon or other device is needed to maintain the integrity of any cavity—indeed, no cavity is formed during the interstitial laser therapy. Thus, the disclosed apparatus enables delivery of uniform x-ray or other therapeutic energy during a brachytherapy treatment using a substantially simplified device and immediately following another therapy, such as interstitial laser therapy. It should be further appreciated that the apparatus disclosed herein is not limited to the apparatus illustrated in FIG. 7B—rather, the apparatus of FIG. 7B is merely exemplary. For example, instead of directing x-ray or other therapeutic energy into the tissue mass 714 using a fiber 712, the disclosed apparatus could utilize one or more brachytherapy seeds or other energy sources to generate and direct such energy.


It should be appreciated that the present disclosure is not limited to a therapeutic system for performing interstitial laser energy therapy and brachytherapy, and particularly, is not limited to a therapeutic system for applying laser energy and x-ray energy to a tumor mass in a breast. The present disclosure may apply to a variety of different non-surgical treatments for the destruction of a variety of different tumor masses.


In various embodiments, certain components of the system disclosed herein are usable to deliver various combinations of x-ray energy, laser energy, and other types of therapeutic energy to tissue to be treated during a single treatment. In one embodiment, the single treatment includes delivery of therapeutic energy, but does not include further removal of tissue to be treated. In another embodiment, the system disclosed herein is usable in conjunction with, in combination with, or coincident to known procedures for surgical excision of tissue to enhance the results of a single treatment. In an example embodiment, certain components of the disclosed system are usable coincident to a known lumpectomy procedure to treat tissue and to enhance the results obtained from such treatment. In other embodiments, the components of the system disclosed herein are usable to perform other types of surgical excision of tissue known to one of ordinary skill in the art.


It should be understood that modifications and variations may be effected without departing from the scope of the novel concepts of the present disclosure, and it should be understood that this application is to be limited only by the scope of the appended claims.

Claims
  • 1. A therapeutic energy application system comprising: a laser energy source;an x-ray energy source;an energy probe insertable into a tissue at a first position;a stylet removably insertable into the energy probe, wherein the stylet is in the energy probe when the energy probe is inserted into the tissue, and wherein the stylet is configured to be removed from the energy probe after the energy probe is inserted into the tissue at the first position;a laser optical fiber configured to be connectable to the laser energy source, the laser optical fiber removably insertable into the energy probe after the stylet is removed from the energy probe, and configured to emit laser energy to heat and ablate tissue;an x-ray optical fiber configured to be connectable to the x-ray energy source, the x-ray optical fiber removably insertable into the energy probe after the stylet is removed from the energy probe and when the laser optical fiber is not in the energy probe;a sensing probe separate from the energy probe, the sensing probe configured to be independently and separately inserted into the tissue at a second position spaced apart from the first position and configured to detect at least one temperature; andat least one microprocessor configured to co-act with the laser energy source, the x-ray energy source, and the at least one sensing probe to: send a signal to the laser energy source to change the amount of laser energy generated,receive a signal from the at least one sensing probe indicating a detected temperature, andsend a signal the x-ray energy source to change the amount of x-ray energy generated.
  • 2. The therapeutic energy application system of claim 1, including at least one display device configured to co-act with the at least one microprocessor to display a graphical representation of the signal from the sensing probe indicating a detected temperature.
  • 3. The therapeutic energy application system of claim 1, including at least one input device configured to co-act with the at least one microprocessor to enable an operator to cause the at least one microprocessor to send a signal to the laser energy source to change the amount of laser energy emitted.
  • 4. The therapeutic energy application system of claim 1, including at least one storage device configured to co-act with the at least one microprocessor to store the signal from the sensing probe indicating a detected temperature.
  • 5. The therapeutic energy application system of claim 1, including at least one input device configured to co-act with the at least one microprocessor to enable an operator to cause the at least one microprocessor to send a signal to the x-ray energy source to change the amount of x-ray energy emitted.
  • 6. The therapeutic energy application system of claim 1, wherein the microprocessor is further configured to co-act with the laser energy source, the x-ray energy source, and the sensing probe, to send a signal to at least one of the laser energy source and the x-ray energy source to cause at least one of the laser energy source and the x-ray energy source to stop emitting energy.
  • 7. The therapeutic energy application system of claim 1, wherein the at least one energy probe includes a substantially constant diameter along the energy probe, such that the energy probe does not maintain a cavity during an application of therapeutic energy.
  • 8. The therapeutic energy application system of claim 7, which does not include a balloon.
  • 9. The therapeutic energy application system of claim 1, wherein a surgical excision of tissue is performed coincident to the at least one microprocessor co-acting with the laser energy source, the x-ray energy source, and the sensing probe.
  • 10. The therapeutic energy application system of claim 1, wherein the sensing probe is configured to detect at least one dosage amount.
  • 11. The therapeutic energy application system of claim 10, including at least one display device configured to co-act with the at least one microprocessor to display a graphical representation of the signal from the sensing probe indicating a detected temperature and to display a graphical representation of the signal from the sensing probe indicating a detected dosage amount.
  • 12. The therapeutic energy application system of claim 10, including at least one storage device configured to co-act with the at least one microprocessor to store the signal from the sensing probe indicating a detected temperature and to store the signal from the sensing probe indicating a detected dosage amount.
PRIORITY CLAIM

This application is a non-provisional application of, claims priority to, and the benefit of U.S. Provisional Patent Application No. 61/177,861, filed May 13, 2009, the entire contents of which are incorporated herein by reference.

US Referenced Citations (437)
Number Name Date Kind
4190461 Hedger Feb 1980 A
4510924 Gray Apr 1985 A
4763671 Goffinet Aug 1988 A
4815449 Horowitz Mar 1989 A
4976680 Hayman et al. Dec 1990 A
5084001 Van't Hooft et al. Jan 1992 A
5141487 Liprie Aug 1992 A
5153900 Nomikos et al. Oct 1992 A
5169396 Dowlatshahi et al. Dec 1992 A
5222953 Dowlatshahi Jun 1993 A
5339812 Hardy et al. Aug 1994 A
5411477 Saab May 1995 A
5428658 Oettinger et al. Jun 1995 A
5429582 Williams Jul 1995 A
5569240 Dowlatshahi et al. Oct 1996 A
5695479 Jagpal Dec 1997 A
5713828 Coniglione Feb 1998 A
5807395 Mulier et al. Sep 1998 A
5853366 Dowlatshahi Dec 1998 A
5868757 Koutrouvelis Feb 1999 A
5997463 Cutrer Dec 1999 A
6048299 Hoffmann Apr 2000 A
6066083 Slater et al. May 2000 A
6083148 Williams Jul 2000 A
6086942 Carden, Jr. et al. Jul 2000 A
6099458 Robertson Aug 2000 A
6106517 Zupkas Aug 2000 A
6129670 Burdette et al. Oct 2000 A
6132359 Bolenbaugh Oct 2000 A
6159141 Apple et al. Dec 2000 A
6163947 Coniglione Dec 2000 A
6179768 Loffler et al. Jan 2001 B1
6196963 Williams Mar 2001 B1
6196964 Loffler et al. Mar 2001 B1
6210312 Nagy Apr 2001 B1
6210315 Andrews et al. Apr 2001 B1
6213932 Schmidt Apr 2001 B1
6213976 Trerotola Apr 2001 B1
6221003 Sierocuk et al. Apr 2001 B1
6224536 Pike May 2001 B1
6248057 Mavity et al. Jun 2001 B1
6251059 Apple et al. Jun 2001 B1
6267718 Vitali et al. Jul 2001 B1
6285735 Sliski et al. Sep 2001 B1
6287249 Tam et al. Sep 2001 B1
6299856 DeVore et al. Oct 2001 B1
6315979 Simon et al. Nov 2001 B1
6319188 Lovoi Nov 2001 B1
6320932 Dinsmore Nov 2001 B2
6320935 Shinar et al. Nov 2001 B1
6327490 Spetz Dec 2001 B1
6347443 Coniglione Feb 2002 B2
6352500 Halpern Mar 2002 B1
6352501 Urick Mar 2002 B1
6358195 Green et al. Mar 2002 B1
6360116 Jackson, Jr. et al. Mar 2002 B1
6361487 Green et al. Mar 2002 B1
6366796 Yanof et al. Apr 2002 B1
6387034 Lee May 2002 B1
6390967 Forman et al. May 2002 B1
6390968 Harmon May 2002 B1
6391026 Hung et al. May 2002 B1
6391279 Singh et al. May 2002 B1
6398711 Green et al. Jun 2002 B1
6402677 Jacobs Jun 2002 B1
6413204 Winkler et al. Jul 2002 B1
6415921 Ye et al. Jul 2002 B2
6416531 Chen Jul 2002 B2
6419621 Sioshansi et al. Jul 2002 B1
6419866 Karl et al. Jul 2002 B1
6436026 Sioshansi et al. Aug 2002 B1
6450937 Mercereau et al. Sep 2002 B1
6450938 Miller Sep 2002 B1
6471631 Slater et al. Oct 2002 B1
6477426 Fenn et al. Nov 2002 B1
6493419 Dinsmore Dec 2002 B1
6494835 Ciezki et al. Dec 2002 B1
6500108 Sorensen et al. Dec 2002 B1
6527693 Munro, III et al. Mar 2003 B2
6530873 Lee Mar 2003 B1
6530875 Taylor et al. Mar 2003 B1
6537195 Forman Mar 2003 B2
6539247 Spetz Mar 2003 B2
6551232 Rivard Apr 2003 B1
6554756 Schaart Apr 2003 B1
6558309 Hogendijk et al. May 2003 B2
6561967 Schmidt May 2003 B2
6572526 Ford Jun 2003 B1
6575888 Zamora et al. Jun 2003 B2
6579262 Mick et al. Jun 2003 B1
6582354 Ellard Jun 2003 B2
6582417 Ledesma et al. Jun 2003 B1
6585633 Vitali et al. Jul 2003 B2
6589173 Mitragotri Jul 2003 B1
6589502 Coniglione et al. Jul 2003 B1
6603988 Dowlatshahi Aug 2003 B2
6607476 Barnhart Aug 2003 B1
6607478 Williams Aug 2003 B2
6608277 Spooner et al. Aug 2003 B2
6610013 Fenster et al. Aug 2003 B1
6615070 Lee Sep 2003 B2
6626817 Luth Sep 2003 B2
6632176 McIntire et al. Oct 2003 B2
6638205 Chan et al. Oct 2003 B1
6638206 Green et al. Oct 2003 B2
6639237 Pedersen et al. Oct 2003 B2
6641518 Wolfson et al. Nov 2003 B2
6648811 Sierocuk et al. Nov 2003 B2
6652442 Gatto Nov 2003 B2
6656107 Pedersen et al. Dec 2003 B1
6659105 Burbank et al. Dec 2003 B2
6659933 Asano Dec 2003 B2
6669621 O'Hara et al. Dec 2003 B2
6673006 Winkler Jan 2004 B2
6676590 Urick et al. Jan 2004 B1
6676595 Delfino Jan 2004 B1
6676658 Burbank et al. Jan 2004 B2
6679824 Reed et al. Jan 2004 B1
6682471 Steele, Sr. et al. Jan 2004 B2
6685618 Tam et al. Feb 2004 B2
6685619 Halpern et al. Feb 2004 B2
6689043 McIntire et al. Feb 2004 B1
6689811 Koumenis et al. Feb 2004 B2
6692587 Ro et al. Feb 2004 B2
6695760 Winkler et al. Feb 2004 B1
6695787 Hogendijk et al. Feb 2004 B2
6699171 Harmon Mar 2004 B2
6701175 Dowlatshahi Mar 2004 B2
6703375 Buchsbaum et al. Mar 2004 B2
6706014 Banik et al. Mar 2004 B2
6706699 Wang et al. Mar 2004 B2
6709380 Green et al. Mar 2004 B2
6709381 Munro, III Mar 2004 B2
6712782 Ford Mar 2004 B2
6712816 Hung et al. Mar 2004 B2
6713462 Metcalf, III et al. Mar 2004 B2
6716156 Menuhr et al. Apr 2004 B2
6727225 Wiley Apr 2004 B2
6730013 Shank et al. May 2004 B1
6746392 Stiger et al. Jun 2004 B2
6746393 Mawad Jun 2004 B2
6746465 Diederich et al. Jun 2004 B2
6746661 Kaplan Jun 2004 B2
6749553 Brauckman et al. Jun 2004 B2
6749555 Winkler et al. Jun 2004 B1
6752752 Geitz Jun 2004 B2
6752753 Hoskins et al. Jun 2004 B1
6755775 Kalas et al. Jun 2004 B2
6761679 Sajo et al. Jul 2004 B2
6761680 Terwilliger et al. Jul 2004 B2
6770021 Halpern Aug 2004 B2
6773390 McDaniel Aug 2004 B2
6778850 Adler et al. Aug 2004 B1
6786858 Terwilliger et al. Sep 2004 B2
6788977 Fenn et al. Sep 2004 B2
6790170 Moody et al. Sep 2004 B2
6792073 Deasy et al. Sep 2004 B2
6796936 Slater et al. Sep 2004 B2
6799075 Chornenky et al. Sep 2004 B1
6800055 Amols et al. Oct 2004 B2
6809517 McGee et al. Oct 2004 B2
6811779 Rockwell et al. Nov 2004 B2
6817995 Halpern Nov 2004 B1
6820318 Terwilliger et al. Nov 2004 B2
6824507 Miller Nov 2004 B2
6824773 Wiley Nov 2004 B2
6837844 Ellard et al. Jan 2005 B1
6846282 Ford Jan 2005 B1
6846283 Green et al. Jan 2005 B2
6847700 Mitra et al. Jan 2005 B1
6847838 Macey et al. Jan 2005 B1
6856668 Thomson et al. Feb 2005 B1
6861044 Simon et al. Mar 2005 B2
6863654 Zappala et al. Mar 2005 B2
6865412 Dowlatshahi Mar 2005 B2
6866624 Chornenky et al. Mar 2005 B2
6867305 Danishefsky et al. Mar 2005 B2
6869390 Elliott et al. Mar 2005 B2
6869588 Weller et al. Mar 2005 B2
6878697 Metcalf, III et al. Apr 2005 B2
6890950 Boothman et al. May 2005 B2
6910999 Chin et al. Jun 2005 B2
6919067 Filler et al. Jul 2005 B2
6921769 Danishefsky et al. Jul 2005 B2
6923754 Lubock Aug 2005 B2
6949064 Lowery et al. Sep 2005 B2
6953426 Barber et al. Oct 2005 B2
6955640 Sanders et al. Oct 2005 B2
6955641 Lubock Oct 2005 B2
6957108 Turner et al. Oct 2005 B2
6960572 Shakespeare et al. Nov 2005 B2
6965847 Wessol et al. Nov 2005 B2
6967198 Benedict et al. Nov 2005 B2
6976949 Winkler et al. Dec 2005 B2
6985557 Jaafar Jan 2006 B2
6986880 Coniglione et al. Jan 2006 B2
6987835 Lovoi Jan 2006 B2
6989486 Lovoi et al. Jan 2006 B2
6994688 Brauckman et al. Feb 2006 B2
6997861 Halpern et al. Feb 2006 B2
6997862 Terwilliger et al. Feb 2006 B2
7008368 Terwilliger et al. Mar 2006 B2
7008633 Yang et al. Mar 2006 B2
7009054 Wang et al. Mar 2006 B2
7018371 Forman Mar 2006 B2
7019139 Metcalf, III et al. Mar 2006 B2
7025717 Tarone et al. Apr 2006 B2
7031432 Geitz Apr 2006 B2
7037252 Flanagan et al. May 2006 B2
7041046 Forman May 2006 B2
7041047 Gellman et al. May 2006 B2
7041048 Drobnik et al. May 2006 B2
7041109 Dowlatshahi May 2006 B2
7048717 Frassica May 2006 B1
7060020 Terwilliger et al. Jun 2006 B2
7064211 Kowalczyk et al. Jun 2006 B2
7066872 Waksman et al. Jun 2006 B2
7067475 Cerretti et al. Jun 2006 B2
7070554 White et al. Jul 2006 B2
7074291 Terwilliger et al. Jul 2006 B2
7074408 Fanslow, III et al. Jul 2006 B2
7077800 Gross et al. Jul 2006 B2
7083566 Tornes et al. Aug 2006 B2
7091343 Bebbington et al. Aug 2006 B2
7094198 Terwilliger et al. Aug 2006 B2
7107089 Lee Sep 2006 B2
7109505 Sliski et al. Sep 2006 B1
7115589 Weigele et al. Oct 2006 B2
7115651 Danishefsky et al. Oct 2006 B2
7118523 Loffler et al. Oct 2006 B2
7118524 Rivard Oct 2006 B2
7122552 Ledford Oct 2006 B2
7127033 Lovoi et al. Oct 2006 B2
7130380 Lovoi et al. Oct 2006 B2
7131942 Taylor et al. Nov 2006 B2
7132427 Wang et al. Nov 2006 B2
7132533 Benedict et al. Nov 2006 B2
7158612 Rusch et al. Jan 2007 B2
7171253 Dowlatshahi Jan 2007 B2
7175635 Loser Feb 2007 B2
7175849 Baum et al. Feb 2007 B2
7179826 Bebbington et al. Feb 2007 B2
7179912 Halbrook et al. Feb 2007 B2
7182726 Williams et al. Feb 2007 B2
7187800 Hibbard Mar 2007 B2
7190895 Groves et al. Mar 2007 B1
7192972 Kowalczyk et al. Mar 2007 B2
7196090 Connolly et al. Mar 2007 B2
7198783 Morris et al. Apr 2007 B2
7200203 Cocks et al. Apr 2007 B2
7201715 Burdette et al. Apr 2007 B2
7201890 Goldenberg Apr 2007 B2
7201906 Cheung Apr 2007 B2
7204986 Cheung Apr 2007 B2
7204987 Cheung Apr 2007 B2
7204988 Cheung Apr 2007 B2
7208158 Cheung Apr 2007 B2
7208500 Lou et al. Apr 2007 B2
7208517 Winn et al. Apr 2007 B1
7211039 Lamoureux May 2007 B2
7211055 Diederich et al. May 2007 B2
7214368 Rasmussen et al. May 2007 B2
7214377 Cheung May 2007 B2
7217242 Alam et al. May 2007 B2
7228579 Tidwell Jun 2007 B2
7252630 Terwilliger et al. Aug 2007 B2
7267643 Koster et al. Sep 2007 B2
7313430 Urquhart et al. Dec 2007 B2
7322928 Reed et al. Jan 2008 B2
7322929 Lovoi Jan 2008 B2
7329242 Peery Feb 2008 B2
7344490 Shaw et al. Mar 2008 B2
7344533 Pearson et al. Mar 2008 B2
7351193 Forman et al. Apr 2008 B2
7354391 Stubbs Apr 2008 B2
7357770 Cutrer et al. Apr 2008 B1
7361134 Rozenfeld et al. Apr 2008 B2
7361135 Drobnik et al. Apr 2008 B2
7396354 Rychnovsky et al. Jul 2008 B2
7399977 Rink et al. Jul 2008 B2
7410458 Bray et al. Aug 2008 B2
7419487 Johnson et al. Sep 2008 B2
7422588 Mulier et al. Sep 2008 B2
7425194 Baltas et al. Sep 2008 B2
7725155 Dowlatshahi May 2010 B2
20010055589 Smilowitz et al. Dec 2001 A1
20020010500 Chen Jan 2002 A1
20020010502 Trachtenberg Jan 2002 A1
20020077521 Green et al. Jun 2002 A1
20020091315 Spetz Jul 2002 A1
20020151778 Dowlatshahi Oct 2002 A1
20020169354 Munro, III Nov 2002 A1
20020169410 Ford Nov 2002 A1
20020177748 Munro, III Nov 2002 A1
20020193654 Mawad Dec 2002 A1
20030018233 Miller Jan 2003 A1
20030045769 Kalas et al. Mar 2003 A1
20030083566 Dowlatshahi May 2003 A1
20030092956 Williams May 2003 A1
20030092958 Terwilliger et al. May 2003 A1
20030097035 Tucker et al. May 2003 A1
20030130711 Pearson et al. Jul 2003 A1
20030153850 Davis et al. Aug 2003 A1
20030158515 Gonzalez et al. Aug 2003 A1
20030171637 Terwilliger et al. Sep 2003 A1
20030171638 Schaart Sep 2003 A1
20030176759 Hogendijk et al. Sep 2003 A1
20030212302 Rozenfeld et al. Nov 2003 A1
20030229282 Burdette et al. Dec 2003 A1
20030233136 Williams et al. Dec 2003 A1
20040010290 Schroeppel et al. Jan 2004 A1
20040068157 Gellman et al. Apr 2004 A1
20040077919 Drobnik et al. Apr 2004 A1
20040102671 Terwilliger et al. May 2004 A1
20040106840 Kindlein et al. Jun 2004 A1
20040109823 Kaplan Jun 2004 A1
20040111004 Loffler et al. Jun 2004 A1
20040116767 Lebovic et al. Jun 2004 A1
20040116914 Dowlatshahi Jun 2004 A1
20040133195 Solomon Jul 2004 A1
20040138515 White et al. Jul 2004 A1
20040152973 Lee Aug 2004 A1
20040162458 Green et al. Aug 2004 A1
20040186340 Reed et al. Sep 2004 A1
20040192998 Brauckman et al. Sep 2004 A1
20040210101 Winkler Oct 2004 A1
20040225176 Flanagan et al. Nov 2004 A1
20040230087 Terwilliger et al. Nov 2004 A1
20040243200 Turner et al. Dec 2004 A1
20040254418 Munro et al. Dec 2004 A1
20050000525 Klimberg et al. Jan 2005 A1
20050004507 Schroeppel et al. Jan 2005 A1
20050011526 Forman et al. Jan 2005 A1
20050027156 Pulido et al. Feb 2005 A1
20050027196 Fitzgerald Feb 2005 A1
20050031648 Brin et al. Feb 2005 A1
20050049508 Forman et al. Mar 2005 A1
20050070753 Forman et al. Mar 2005 A1
20050075529 Pedersen et al. Apr 2005 A1
20050080313 Stewart et al. Apr 2005 A1
20050080340 Stewart et al. Apr 2005 A1
20050085681 Stubbs et al. Apr 2005 A1
20050096515 Geng May 2005 A1
20050101824 Stubbs May 2005 A1
20050101825 Winkler et al. May 2005 A1
20050101826 Bray et al. May 2005 A1
20050107653 Patrick et al. May 2005 A1
20050119725 Wang et al. Jun 2005 A1
20050124844 Forman Jun 2005 A1
20050184424 Ferguson Aug 2005 A1
20050187422 Maschke Aug 2005 A1
20050191207 Terwilliger et al. Sep 2005 A1
20050251235 Schlorff et al. Nov 2005 A1
20050261541 Henderson et al. Nov 2005 A1
20050267319 White et al. Dec 2005 A1
20050277802 Larsen et al. Dec 2005 A1
20060017009 Rink et al. Jan 2006 A1
20060023843 Kusch Feb 2006 A1
20060058568 Gross et al. Mar 2006 A1
20060063961 Drobnik et al. Mar 2006 A1
20060063962 Drobnik et al. Mar 2006 A1
20060067467 Chornenky et al. Mar 2006 A1
20060069298 Terwilliger et al. Mar 2006 A1
20060074303 Chornenky et al. Apr 2006 A1
20060089520 Terwilliger et al. Apr 2006 A1
20060100475 White et al. May 2006 A1
20060100476 Biscotti May 2006 A1
20060111605 Larsen et al. May 2006 A1
20060116546 Eng Jun 2006 A1
20060122452 van't Hooft Jun 2006 A1
20060167332 Bray Jul 2006 A1
20060173232 Lovoi et al. Aug 2006 A1
20060173233 Lovoi Aug 2006 A1
20060173235 Lim et al. Aug 2006 A1
20060173236 White et al. Aug 2006 A1
20060183959 Sioshansi et al. Aug 2006 A1
20060183960 Sioshansi et al. Aug 2006 A1
20060184018 Cox et al. Aug 2006 A1
20060224035 Russell et al. Oct 2006 A1
20060235260 Mourtada et al. Oct 2006 A1
20060235365 Terwilliger et al. Oct 2006 A1
20060241332 Klein et al. Oct 2006 A1
20060241727 Dowlatshahi Oct 2006 A1
20070015837 Kun et al. Jan 2007 A1
20070016062 Park et al. Jan 2007 A1
20070021643 Lamoureux et al. Jan 2007 A1
20070027352 Mourtada et al. Feb 2007 A1
20070038014 Cox et al. Feb 2007 A1
20070049786 Edmundson Mar 2007 A1
20070055090 Neustadter et al. Mar 2007 A1
20070074347 Coppens et al. Apr 2007 A1
20070075277 Smith et al. Apr 2007 A1
20070084474 Rivard Apr 2007 A1
20070100229 Dowlatshahi May 2007 A1
20070106108 Hermann et al. May 2007 A1
20070123815 Mark May 2007 A1
20070135873 Johansson et al. Jun 2007 A1
20070140426 Axelrod et al. Jun 2007 A1
20070142694 Cutrer et al. Jun 2007 A1
20070142695 White et al. Jun 2007 A1
20070149571 Stein et al. Jun 2007 A1
20070167665 Hermann et al. Jul 2007 A1
20070173680 Rioux et al. Jul 2007 A1
20070219488 Francescatti Sep 2007 A1
20070270627 Cutrer et al. Nov 2007 A1
20070288075 Dowlatshahi Dec 2007 A1
20080004478 Francescatti et al. Jan 2008 A1
20080004524 Francescatti et al. Jan 2008 A1
20080004543 Davies Jan 2008 A1
20080009658 Smith et al. Jan 2008 A1
20080009659 Smith et al. Jan 2008 A1
20080071132 Lamoureux et al. Mar 2008 A1
20080086026 Keppel et al. Apr 2008 A1
20080091056 Kaplan Apr 2008 A1
20080103104 Moore et al. May 2008 A1
20080118518 Cirrito et al. May 2008 A1
20080154085 Jervis et al. Jun 2008 A1
20080154086 Stubbs Jun 2008 A1
20080177127 Allan et al. Jul 2008 A1
20080185314 Tomasello et al. Aug 2008 A1
20080188841 Tomasello et al. Aug 2008 A1
20080188842 Tomasello et al. Aug 2008 A1
20080194985 Nicoson et al. Aug 2008 A1
20080208052 LePivert et al. Aug 2008 A1
20080214887 Heanue et al. Sep 2008 A1
20080221384 Chi Sing et al. Sep 2008 A1
20080221443 Ritchie et al. Sep 2008 A1
20080221444 Ritchie et al. Sep 2008 A1
20080221478 Ritchie et al. Sep 2008 A1
20080221479 Ritchie et al. Sep 2008 A1
20080293994 Francescatti et al. Nov 2008 A1
20080300443 Lovoi Dec 2008 A1
20080300445 Francescatti et al. Dec 2008 A1
20080306322 Jervis et al. Dec 2008 A1
20080306323 Jervis et al. Dec 2008 A1
20090030258 Axelrod et al. Jan 2009 A1
20100222647 Hashimshony et al. Sep 2010 A1
Non-Patent Literature Citations (19)
Entry
A fibre optic scintillator dosimeter for absorbed dose measurements of low-energy X-ray-emitting brachytherapy sources, Sliski, Alan et al., Radiation Protection Dosimetry, Jun. 16, 2006.
A Novel real-time dosimetry technique based on radiation-induced surface activation, H. Tomozawa et al., Apr. 27, 2006.
Advanced X-Ray Technology, Inc., website, downloaded from http://www.axt-medical.com/products/softray, Jan. 15, 2008.
Advanced X-Ray Technology Devices—Description, website, http://www.axt-medical.com, downloaded Nov. 29, 2007.
Brachytherapy—definition, RadiologyInfo website, http://www.radiologyinfo/org/en/info.cfm?pg=brachy&bhcp=1, downloaded Nov. 29, 2007.
Brachytherapy—Wikipedia definition, website, http://en.wikipedia.org/wiki/Brachytherapy, downloaded Nov. 29, 2007.
Breast Cancer—defintion, RadiologyInfo website, http://www.radiologyinfo/org/en/info.cfm?pg=breastcancer , downloaded Nov. 29, 2007.
Critical Technology for In-Space Application of Nuclear Thermal Propulsion—Real-Time Micro-Miniature Dosimeter, NASA SBIR 2005 Solicitation, website, http://sbir.gsfc.nasa.gov/SBIR/abstracts/05/sbir/phase1/sbir-05-1-X10.03-8601.html, downloaded Nov. 29, 2007.
Dosimeter—Wikipedia definition, website, http://en.wikipedia.org/wiki/Dosimeter, downloaded Nov. 29, 2007.
Dosimetrists—definition, RadiologyInfo website, http://www.radiologyinfo.org/en/glossary/glossary1.cfm?Term=dosimetrist&bhcp=1, downloaded Nov. 29, 2007.
HDR Brachytherapy Article, website, http://www.cancercenter.com/conventional-cancer-treatment/hdr-brachytherapy.cfm, website, downloaded Nov. 29, 2007.
MammoSite 5-Day Target Radiation Therapy: How It Works, website, http://www.mammosite.com/breast-lumpectomy/ow-it-works.cfm, downloaded Nov. 29, 2007.
Neutron Spectrometer, Real-Time Dosimeter and Methodology Using Three-Dimensional Optical Memory, website, http://otl.georgetown.edu/industry/inventions/moma430503.html, downloaded Nov. 29, 2007.
Portable Waterphantom Scanning System, website, downloaded from http://www.multidata-systems.com/rtdwph.asp?wph=port, downloaded Nov. 29, 2007.
RTD (Realtime Dosimetry System), website, downloaded from http://www.multidata-systems.com/rtd—prodpg.asp, downloaded Nov. 29, 2007.
Source 1 X-Ray, website, downloaded from http://www.source1xray.com/glenbrook—detail.html, Jan. 15, 2008.
Stereotactic-guided laser-induced interstitial thermotherapy (SLITT) in gliomas with interoperative morphologic monitoring in open MRI—Abstract, Lumenta, Christiano et al. (Proc. SPIE vol. 4156, Jan. 2001.
Wallet Card Dosimeters, website, downloaded from http://www.stanforddosimetery.com/SIRAD/walletdosimeter.html, Nov. 29, 2007.
X-ray scalpel—new device for target x-ray brachytherapy and stereotactic radiosurgery—Abstract, Gutman, George et al., Mar. 2007.
Related Publications (1)
Number Date Country
20100292682 A1 Nov 2010 US
Provisional Applications (1)
Number Date Country
61177861 May 2009 US